IL10 and hematologic disorder: Conversely, a meta-analysis of serum IL-10 in 1788 cancer patients showed that high seurm IL-10 levels were significantly associated with worse OS and disease-free survival (DFS) at 1 year, 3 years, and 5 years for both solid and hematological malignancies [206].